Frontlight ResearchEarly access
Active, not recruitingNo phase
INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE
Key facts
- Who runs it
- Brixton Biosciences, Inc.
- Where
- Boston, Chicago, Edmond, Flint, Gainesville, Houston, Johns Creek, Larkspur, New Orleans, North Bethesda, San Antonio, Sewickley, Tulsa, Washington D.C., and Wichita, United StatesSee the 15 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 263 people, planned
- Started
- 19 Nov 2024
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Neural Ice
- Triamcinolone acetate
- Record updated
- 28 October 2025
Who can take part
- Age
- 22 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Age 22 to 80, inclusive of any gender
- Baseline pain intensity of >/= 5 of the Numeric Rating Scale (NRS) despite current treatment Confidential Brixton Biosciences Inc. Page 12 of 53 Version: 1.1, 30 August 2024
- Chronic symptomatic osteoarthritis of the knee (K-L stage 2, 3, or 4) on plain x-rays obtained within the previous 12 months
- At least 3 months of previous conservative treatments (NSAID, acetaminophen, physical therapy, cortisone injections) that are not currently providing relief
- Agree to see one doctor (study investigator) for knee pain during the study period
- Willing/able to understand the informed consent form and provide written informed consent
- Able to complete outcome measures (including electronic patient reported outcome measures)
Who cannot take part
- Currently taking >60 MME/day, as determined per MDcalc.com (opioid conversion calculator)
- Any condition or circumstance that would impact or confound assessment of safety and/or pain. For example, comorbid or concomitant pain conditions, pre-existing lower limb neurologic deficits, any psychiatric or neurologic disease
- Participation in any clinical study of a therapeutic investigational product within 30 days prior to enrollment
- Known allergy to glycerol, hyaluronic acid, poloxamer 407, or phosphate buffered saline
- History of cryoglobulinemia
- History of cold-induced auto-immune hemolytic anemia (e.g. paroxysmal cold hemoglobinuria or cold agglutinin disease)
- History of cold urticaria
- History of Chilblain's (pernio) disease in the lower extremities
- History of Raynaud's disease
- Open and/or infected wounds or active tumor at or near the treatment site
- History of vascular surgery involving femoral vessels on the injection side
- History of surgical procedures to affected limb that, in the opinion of the investigator, could have impacted the integrity of the genicular nerves or blood vessels
- Active bacterial or fungal infection that at the discretion of the investigator would preclude study participation
- History of History of systemic inflammatory conditions such as rheumatoid arthritis
- Bleeding disorders anticoagulant therapy, unless appropriately stopped or reversed for the procedure
- Any condition (such as history of significant cardiovascular, renal failure/dialysis, hepatic or other systemic comorbidity/chronic pain condition) or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of study data
- Use of intra-articular injection of corticosteroid within the previous 3 months, or hyaluronic acid, prolotherapy, Confidential Brixton Biosciences Inc. Page 13 of 53 Version: 1.1, 30 August 2024 autologous blood, or platelet rich plasma injections for the index knee within the previous 6 months
- Cryoneurolysis, thermal or pulsed radiofrequency ablation, or phenol injection for the index knee within the past 12 months
- Known contraindication to use of a regional anesthetic block
- Pregnant, nursing or intent of becoming pregnant during the study period
- Body habitus/knee anatomy that would preclude the use of the product injection needle size
- Unwilling to refrain from participation in any other clinical study through the duration of this study
- Unwilling to refrain from any scheduled surgeries during the duration of this study
Where in United States
- Brigham and Women's HospitalBoston, United States
- Insight Hospital and Medical Center ChicagoChicago, United States
- Clinical Investigations, LLCEdmond, United States
- Insight Research InstituteFlint, United States
- The Orthopaedic InstituteGainesville, United States
- NextStage Clinical Research All-American Orthopedic & Sports Medicine InstituteHouston, United States
- Emory UniversityJohns Creek, United States
- Marin HealthLarkspur, United States
- Ochsner Health SystemNew Orleans, United States
- NextStage Clinical Research Regenerative Orthopedics and Sports MedicineNorth Bethesda, United States
- UT San AntonioSan Antonio, United States
- Pain Diagnostics and Interventional CareSewickley, United States
- NextStage Clinical Research The Orthopedic CenterTulsa, United States
- Centers for Advanced OrthopedicsWashington D.C., United States
- NextStage Clinical Research Advanced Orthopaedic AssociatesWichita, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the effectiveness of Neural Ice for pain management associated with knee osteoarthritis in adults aged 22-80 years. Participants will attend study visits and complete subject diaries. Participants will be followed for 6 months after study procedure.
The 2 groups in the trial
- Neural Ice injectionsTreatment being tested
This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
Treatment: Neural Ice
- Corticosteroid injectionExisting treatment, for comparison
Intraarticular corticosteroid injection is defined as a single dose of Triamcinolone 40mg injected directly into the joint space.
Treatment: Triamcinolone acetate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE: A MULTI-CENTER, RANDOMIZED, CONTROLLED STUDY (ICE STUDY)
- Record updated
- 28 October 2025